How long does it take to effectively reduce pulmonary arterial hypertension after taking macitentan (Aopuxil)?

Macitentan (Macitentan) is an oral endothelin receptor antagonist mainly used to treat pulmonary arterial hypertension (PAH). It inhibits vasoconstriction and vascular remodeling by blocking endothelin receptors ETA and ETB, thereby reducing pulmonary artery pressure and improving right heart function. Clinical application shows that macitentan can significantly improve patients' exercise tolerance and quality of life, and is an important drug for the long-term management of pulmonary hypertension.

Typically, hemodynamic and symptomatic improvements are not immediately apparent after macitentan is initiated. Studies have shown that most patients can begin to observe a decrease in pulmonary artery pressure and an improvement in exercise tolerance after taking the drug for 2 to 4 weeks. The efficacy of the drug gradually stabilizes over time, and it usually takes several months of continuous use to achieve the best clinical effect.

Patients may still feel short of breath or weak during the early stages of taking the medication, but this does not mean the medication is ineffective. The effect of macitentan is achieved through long-term regulation of vasoconstriction and vessel wall remodeling, so regular medication is required. At the same time, regular follow-up and examinations, including six-minute walk test, cardiac ultrasound and blood index monitoring, can help evaluate the efficacy and adjust the treatment plan.

In general, macitentan usually starts to take effect in 2 to 4 weeks, but the best effect requires long-term continuous use, and follow-up and dosage management under the guidance of a doctor. Patients should remain patient, insist on taking the medication, and pay attention to observe any adverse reactions, such as edema, hypotension or abnormal liver function, and provide timely feedback to the doctor to ensure safety and efficacy.

Reference materials:https://www.drugs.com/